Long Duration Dual Antiplatelet Treatment Increases Bleeding

This article originally appeared here.
Share this content:
Long Duration Dual Antiplatelet Treatment Increases Bleeding
Long Duration Dual Antiplatelet Treatment Increases Bleeding

WEDNESDAY, Sept. 30, 2015 (HealthDay News) -- Routine use of dual antiplatelet therapy (DAPT) beyond six months after second generation drug-eluting stent (DES) implantation yields mixed clinical results, according to a review published in the October issue of Cardiovascular Therapeutics.

Elsayed Abo-salem, M.D., from the University of Cincinnati, and colleagues conducted a systematic literature search to identify randomized controlled trials (RCTs) comparing the continued use of DAPT with shorter duration of DAPT (aspirin alone) for variable durations beyond three months after DES implantation.

The researchers identified 10 RCTs with 32,136 subjects randomized to continued use of DAPT versus aspirin alone for variable durations after three months of DES implantation. The studies were not significant heterogeneously. Longer DAPT resulted in a significant reduction in stent thrombosis (P < 0.01) and myocardial infarction (P < 0.01), and a significant increase in major bleeding (P < 0.01), compared to shorter DAPT. Cardiac deaths or stroke did not differ by DAPT length. With shorter DAPT, all-cause deaths were slightly lower, compared to longer DAPT (odds ratio, 0.8; P = 0.04).

"DAPT continued beyond six months after second generation DES implantation decreases stent thrombosis and myocardial infarction, but increases major bleeding and all-causes mortality compared to shorter DAPT (aspirin alone)," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

ASTRO: No Survival Benefit for Adding EBT to ...

Addition of external beam therapy doesn't improve five-year progression-free survival in prostate cancer

ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

ASTRO: Fewer Side Effects With IMRT in Cervical, ...

Patients in conventional radiotherapy arm had more high-level adverse events than those in IMRT arm

Many Doctors Reluctant to Reveal Mental Health Issues

Many Doctors Reluctant to Reveal Mental Health Issues

Perceived stigma, fear of career repercussions hinder treatment, study suggests

is free, fast, and customized just for you!

Already a member?

Sign In Now »